Ibogaine and ayahuasca are both plant-derived psychedelics explored for addiction, depression, and trauma. They differ fundamentally in pharmacology, duration, safety profile, and practical access. This page compares both treatments using available research — without advocating for either.

At a Glance

Factor Ibogaine Ayahuasca
Primary Source Tabernanthe iboga root bark (West Africa) Banisteriopsis caapi vine + Psychotria viridis leaves (Amazon)
Mechanism NMDA antagonist, κ/μ-opioid modulation, GDNF upregulation, sigma-2 agonist DMT (5-HT2A agonist) + MAOI (harmaline/harmine)
Evidence Level Phase 1–2 trials; strong observational data for opioid use disorder Observational studies; early-phase trials for depression and addiction
Session Duration 24–36 hours (single session) 4–8 hours per ceremony; typically multiple nights
Legal Status (US) Schedule I; legal in some countries Schedule I (DMT); legal in religious contexts in some jurisdictions
Access Mexico, Costa Rica, New Zealand, Gabon clinics Peru, Brazil, Netherlands, retreat centers globally
Typical Cost $5,000–$15,000+ per treatment $1,500–$5,000 per multi-night retreat
Cardiac Risk Significant — QT prolongation, arrhythmia risk, fatalities reported Lower — serotonin syndrome risk with contraindicated medications
Most Studied For Opioid, stimulant, and alcohol use disorders Depression, PTSD, alcohol use disorder

Mechanism of Action

Ibogaine is pharmacologically unusual. It acts on multiple receptor systems simultaneously: it antagonizes NMDA receptors (similar to ketamine), modulates kappa and mu opioid receptors, and — through its long-lived metabolite noribogaine — may upregulate glial cell line-derived neurotrophic factor (GDNF), a protein associated with neural repair and reduced drug-seeking behavior in animal models. This multi-target profile is believed to underlie its reported ability to interrupt opioid withdrawal and reduce cravings after a single dose.

Ayahuasca works through a distinct mechanism. N,N-dimethyltryptamine (DMT) — the primary psychoactive compound — is a potent agonist at serotonin 5-HT2A receptors, the same receptor class targeted by psilocybin and LSD. Orally, DMT is normally broken down before reaching the brain. The harmala alkaloids in the caapi vine act as monoamine oxidase inhibitors (MAOIs), making DMT orally active and extending the experience. Ayahuasca also promotes neuroplasticity through BDNF signaling, and some researchers propose its antidepressant effects follow similar pathways to other classic psychedelics.

Both substances produce profound altered states, but ibogaine's experience is often described as more introspective and visionary with a dream-like quality, while ayahuasca is frequently characterized as emotionally intense, purging, and interpersonally relational. These phenomenological differences may be therapeutically relevant, though research has not yet established how much the subjective experience contributes to outcomes versus neurobiological changes alone.

Evidence Base

Neither ibogaine nor ayahuasca has completed large-scale Phase 3 randomized controlled trials as of 2026, but the depth of existing evidence differs meaningfully between them.

Ibogaine has the strongest clinical evidence for opioid use disorder. A landmark 2023 Stanford study (Cherian et al.) found that ibogaine treatment in veterans with traumatic brain injury led to significant reductions in PTSD, depression, and disability, with improvements sustained at one-month follow-up. Multiple observational cohort studies — including Noller et al. (2018) in New Zealand and Brown & Alper (2018) — document substantial reductions in opioid and stimulant use following ibogaine treatment. A 2021 systematic review in The American Journal of Drug and Alcohol Abuse concluded that evidence supports further clinical investigation, particularly for opioid use disorder. Phase 2 trials are currently active in several countries.

Ayahuasca has a growing clinical literature, particularly for treatment-resistant depression. Palhano-Fontes et al. (2019) published a randomized placebo-controlled trial (n=29) showing rapid antidepressant effects of ayahuasca versus placebo, with significant differences at day 7. Thomas et al. (2013) reported reduced problematic alcohol and stimulant use in a Canadian observational study. Researchers at the University of São Paulo have published several neuroimaging studies showing changes in default mode network activity. Overall, the ayahuasca evidence base is comparable in development stage to ibogaine — promising but not yet definitive.

📊 Both substances remain in active clinical investigation. Neither is FDA-approved for any indication. Observational data — while compelling — cannot establish causation due to selection bias and lack of control conditions.

Safety Profile

⚠️ Ibogaine carries serious cardiac risks and has caused fatalities. Medical supervision and pre-treatment cardiac screening required.

Ibogaine prolongs the cardiac QT interval, which can trigger life-threatening ventricular arrhythmias including torsades de pointes. A 2012 review by Alper et al. identified at least 19 fatalities associated with ibogaine use globally at that time; subsequent analyses suggest higher numbers when unregulated contexts are included. Risk is substantially elevated by pre-existing cardiac conditions, electrolyte imbalances, concurrent medications (particularly those that also prolong QT), and opioid intoxication. Reputable clinics require 12-lead ECG, comprehensive bloodwork, and a washout period from opioids and other drugs before treatment. When these protocols are followed, serious adverse events appear rare but not eliminated. The long duration of the experience (24–36 hours) also places demands on both the patient and medical team.

Ayahuasca's most significant safety concern is serotonin syndrome — a potentially life-threatening condition that can occur when ayahuasca is combined with SSRIs, SNRIs, MAOIs, tramadol, lithium, or other serotonergic medications. Fatalities in ayahuasca settings have been documented, though they are rare and often involve contraindicated substances, unsafe settings, or inadequate screening. The brew itself can cause nausea, vomiting, and diarrhea (culturally described as "purging") in many participants. Psychological adverse events — including persistent anxiety or psychosis-like states — have been reported, with greater risk in individuals with personal or family history of psychotic disorders. The shorter duration and generally lower cardiac burden make ayahuasca somewhat more medically manageable, but it is not without risk.

Both substances require careful psychological screening. Neither is appropriate for individuals with a personal or family history of schizophrenia, schizoaffective disorder, or bipolar I disorder with psychotic features. Pregnancy is a contraindication for both.

Cost and Access

Ibogaine is more expensive and harder to access than ayahuasca. The complexity of medical monitoring — including cardiac equipment, trained staff, and the 36-hour window — drives costs between $5,000 and $15,000 or more at licensed clinics. The primary legal destinations are Mexico (particularly Tijuana and Puerto Vallarta), Costa Rica, and New Zealand, where it is unscheduled or regulated differently. Some European countries permit ibogaine under specific frameworks. Gabon in West Africa permits traditional iboga ceremonies, which differ substantially from clinical settings. Underground access in countries where ibogaine is scheduled carries substantially higher risk due to absent medical oversight.

Ayahuasca is more globally accessible. Retreat centers operate legally in Peru, Brazil (where the União do Vegetal and Santo Daime churches have legal status), the Netherlands (where ayahuasca exists in a legal gray area), Portugal, and several other countries. Multi-night retreats typically range from $1,500 to $5,000, though luxury wellness retreats can exceed this. Ceremonial contexts led by indigenous Shipibo or other Amazonian practitioners remain available in South America. The lower cost and broader geographic spread make ayahuasca comparatively more accessible, though quality of screening and medical oversight varies enormously across settings.

Who Each May Be Best Suited For

Research and clinical observation suggest some patterns, though individual variation is substantial and neither treatment is appropriate for everyone.

Ibogaine has the most consistent evidence among individuals with opioid use disorder, particularly those seeking to interrupt physical dependence and reduce cravings. It is also being studied for stimulant use disorders, alcohol use disorder, PTSD, and traumatic brain injury. Because of its cardiac risks, it is most appropriate for medically screened individuals without cardiac comorbidities, significant arrhythmia history, or QT-prolonging medications. It tends to attract individuals seeking a single intensive intervention rather than an ongoing ceremonial practice.

Ayahuasca appears more studied and anecdotally used for depression, emotional processing, and trauma integration. Its ceremonial structure — often involving multiple sessions over several days, music, and community — may suit individuals who value relational and spiritual dimensions of healing. It is better tolerated in terms of cardiac risk, though the MAOI interaction profile requires careful medication review. It may be a consideration for individuals who are not candidates for ibogaine due to cardiac concerns but who still seek a psychedelic-assisted approach.

Neither treatment should be considered a substitute for ongoing mental health support, and integration therapy after either experience is widely recommended by clinicians working in this space.

Key Difference

Ibogaine and ayahuasca share a broad category — plant-derived psychedelics explored for mental health and addiction — but diverge significantly in almost every practical dimension. Ibogaine is a single-session, pharmacologically complex intervention with strong mechanistic rationale for opioid use disorder but meaningful cardiac risk requiring medical infrastructure. Ayahuasca is a shorter, often multi-session experience with MAOI-based pharmacology, a broader but earlier-stage evidence base spanning depression and addiction, and a comparatively more accessible global retreat infrastructure. The choice between them, where both are being considered, depends on individual medical history, target condition, risk tolerance, practical access, and personal relationship with ceremonial versus clinical frameworks — factors that cannot be reduced to a simple recommendation.

Frequently Asked Questions

Combining ibogaine and ayahuasca is not recommended and could be dangerous. Ibogaine has complex interactions with many substances, and the harmala alkaloids in ayahuasca (MAOIs) could alter ibogaine metabolism unpredictably. Sequential use requires careful medical guidance and substantial washout periods. No clinical research currently supports a combined protocol, and reputable clinics screen against concurrent use of other psychoactive substances.
Both are in early-to-mid stages of clinical research. Ibogaine has stronger observational evidence specifically for opioid use disorder, with multiple cohort studies and an influential 2023 Stanford trial. Ayahuasca has one published randomized controlled trial for depression (Palhano-Fontes et al., 2019) and a substantial observational literature. Neither has completed Phase 3 trials or achieved regulatory approval for any psychiatric indication.
Ayahuasca carries a lower cardiac risk profile than ibogaine, which is associated with QT prolongation and documented fatalities. However, ayahuasca is not without risk — particularly for individuals on serotonergic medications (SSRI, SNRI, MAOI), those with cardiac conditions, or individuals with a history of psychotic disorders. Both substances have caused serious adverse events in unscreened populations. "Safer" depends heavily on an individual's medical history and the quality of the setting and screening.
Ibogaine experiences are frequently described as a prolonged, often biographical or life-review state — vivid, dream-like, and mentally demanding over 24–36 hours, sometimes without the emotional catharsis typical of other psychedelics. Ayahuasca is often described as emotionally intense and relational, commonly involving physical purging, vivid visual imagery, and a sense of encounter with external presences or archetypal content. Individual variation is significant for both. These phenomenological differences may matter therapeutically, but research has not established how much the subjective experience drives outcomes.
Most clinicians and researchers working with both substances strongly recommend integration support — therapy, coaching, or community — following treatment. Integration refers to the process of making meaning from the experience and translating insights into behavioral change. Ibogaine's single-session nature makes follow-up integration especially important, as the acute experience can surface difficult material without the ongoing ceremonial container that ayahuasca retreats sometimes provide. Evidence for how much integration contributes to outcomes independently of the substance itself remains limited.
Ibogaine has shown antidepressant effects in observational studies — notably in the 2023 Stanford study of veterans — but it has not been rigorously studied as a primary treatment for major depressive disorder in the way ayahuasca has. Ayahuasca currently has more direct clinical evidence for depression, including a placebo-controlled trial. Individuals with depression considering either substance should consult a psychiatrist familiar with psychedelic-assisted therapies, particularly regarding medication interactions and cardiac screening.
Ibogaine is legally accessible at licensed clinics primarily in Mexico, Costa Rica, and New Zealand. It is unscheduled in several other countries. Ayahuasca can be accessed legally or in religious exemption frameworks in Peru, Brazil, the Netherlands, Portugal, and some other countries. Legal landscapes are evolving — Oregon and Colorado have created regulated psychedelic frameworks in the US, though ibogaine and ayahuasca are not yet included. Anyone considering travel for treatment should verify current legal status independently, as regulations change.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.